Legal Representation
Attorney
Maren C. Perry
USPTO Deadlines
Next Deadline
1071 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-06-14)
Due Date
June 14, 2028
Grace Period Ends
December 14, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
37 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 17, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jun 17, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jun 17, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jun 17, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jun 17, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jun 14, 2022 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jun 14, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| May 10, 2022 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| May 8, 2022 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| May 5, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| May 5, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| May 5, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| May 5, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| May 5, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| May 4, 2022 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| May 4, 2022 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| May 2, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Apr 18, 2022 | IUAF | S | USE AMENDMENT FILED |
| Apr 18, 2022 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Jan 25, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jan 25, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jan 25, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jan 4, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Nov 9, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Nov 9, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Oct 20, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Oct 1, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Oct 1, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Oct 1, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Oct 1, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Oct 1, 2021 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Mar 4, 2021 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED |
| Mar 4, 2021 | GPRA | F | PRIORITY ACTION E-MAILED |
| Mar 4, 2021 | CPRA | R | PRIORITY ACTION WRITTEN |
| Mar 1, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Nov 17, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Oct 6, 2020 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations and pharmaceutical compounds for the treatment of disorders of the central nervous system
First Use Anywhere:
Mar 10, 2022
First Use in Commerce:
Mar 10, 2022
Class 042
Scientific and technological services, namely, medical research, scientific research and analysis in the field of pharmaceuticals and biomedicine; pharmaceutical and biomedical research services; scientific research in the fields of pharmaceutical preparations, clinical trials; pharmaceutical research and development; providing scientific research information in the fields of pharmaceuticals, biomedicine and clinical trials; research and development services in the fields of pharmaceuticals and biotechnology; scientific research and development; laboratory research, screening, evaluation, development and clinical testing of therapeutic compounds; scientific research, studies, and development in the field of pharmaceuticals; scientific research and development, namely, pharmaceutical discovery, process development relating to synthesis and scalability for active pharmaceutical ingredients, large scale synthesis of active pharmaceutical ingredients, and formulation development
First Use Anywhere:
Oct 27, 2020
First Use in Commerce:
Oct 27, 2020
Class 044
Providing medical information
First Use Anywhere:
Mar 28, 2022
First Use in Commerce:
Mar 28, 2022
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"